Identifying Acute Cardiac Hazard in Early Drug Discovery Using a Calcium Transient High-Throughput Assay in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Hua Rong Lu1*, Mohamed Kreir1, Van Ammel Karel1, Fetene Tekle2, Danny Geyskens1, Ard Teisman1 and David J. Gallacher1

1Global Safety Pharmacology, Predictive, Investigative and Translational Toxicology, Nonclinical Safety, Beerse, Belgium, 2Discovery and Nonclinical Safety Statistics, Statistics and Decision Sciences, Quantitative Sciences, Janssen R&D, A Division of Janssen Pharmaceutica NV, Beerse, Belgium

Introduction: Early identification of cardiac risk is essential for reducing late-stage attrition in drug development. We adapted the previously published cardiac hazard risk-scoring system using a calcium transient assay in human stem cell-derived CMs for the identification of cardiac risks recorded from the new hiPSC-CM line and investigated its predictivity and translational value based on the screening of a large number of reference and proprietary compounds.

Methods: Evaluation of 55 reference drugs provided the translation of various pharmacological effects into a single hazard label (no, low, high, or very high hazard) using a Ca2+-sensitive fluorescent dye assay recorded by FDSS/µCell Functional Drug Screening System (Hamamatsu on hiPSC-CM line (FCDI iCell Cardiomyocytes2).

Results: Application of the adapted hazard scoring system in the Ca2+ transient assay, using a second hiPS-CM line, provided comparable scoring results and predictivity of hazard, to the previously published scoring approach, with different pharmacological drug classes, as well as screening new chemical entities (NCE’s) using a single hazard label from four different scoring levels (no, low, high, or very high hazard). The scoring system results also showed minimal variability across three different lots of hiPSC-CMs, indicating good reproducibility of the cell line. The predictivity values (sensitivity and specificity) for drug-induced acute cardiac risk for QT-interval prolongation and Torsade de pointes (TdPs) were >95% and statistical modeling confirmed the prediction of proarrhythmic risk. The

Abbreviations: Amp, amplitude; bpm, beats per minute; BR, beat rate; BS, beating stop (cessation of beating); BBQL, below beat qualitative level; CiPA, Comprehensive in vitro Proarrhythmia Assay; CTD, Calcium Transient Duration; DMSO, dimethylsulfoxide; EAD, Early Afterdepolarization; FDA, Food and Drug Administration; FDSS, Functional Drug Screening System; hERG, human ether-a-go-go-related gene; HESI, Health and Environmental Sciences Institute; hSC-CMs, human stem cell-derived cardiomyocytes; hiPSC-CMs, human induced pluripotent stem cell-derived cardiomyocytes; Ikr, rapidly activating delayed rectifier potassium current; NCEs, new chemical entities.; R&D, Research & Development; RLU, Relative light unit; TdP, Torsades de Pointes; VF, Ventricular fibrillation.
INTRODUCTION

Early detection and elimination of new chemical entities (NCEs) with potential cardiac safety risks in drug discovery is essential for reducing late-stage attrition. Importantly, this strategy can reduce the potential risk for participants in clinical studies, and reduce wasted investment costs in late-stage development and increase the likelihood of advancing safe and effective novel therapeutics. The primary focus of cardiac safety within the current regulatory guidelines is to avoid drug-induced potentially life-threatening arrhythmias such as torsade de Pointes (TdP) (Gintant et al., 2016; Lu et al., 2017). TdP is associated with prolongation of QT-interval, which is primarily linked to the inhibition of human ether-a-go-go current (hERG), which encodes the pore forming a-subunit of rapidly activating delayed rectifier current potassium current (I_Kr), in various species including human. In addition to QT prolongation, other pharmacological actions can result in drug-induced cardiac toxicities such as QT shortening (Lu et al., 2008) and QRS widening (Lu et al., 2010), which are also associated with conduction abnormalities and even accompanied with non-TdP-like ventricular tachycardia (VT) or ventricular fibrillation (VF). These later drug-induced cardiac toxicities, which are not related to QT prolongation (or with hERG inhibition), are also to be covered during early drug discovery in pharmaceutical research and development (R&D).

Human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs) are now applied as part of early safety de-risking of NCEs (Authier et al., 2017) (2005, Ovics et al., 2020) and were evaluated in one of the workstream elements of the Comprehensive in vitro Proarrhythmia Assay (CIPA) initiative (Colatsky et al., 2016; Gintant et al., 2016). Within the CIPA workstream, the Myocyte Team, coordinated by the Health and Environmental Sciences Institute (HESI) and the US Food and Drug Administration (FDA), conducted studies with 28 reference drugs known to have different potential risks in humans using various technologies including microelectrode array (MEA) and voltage-sensing optical action potential recording in hiPSC-CMs (Blinova et al., 2018). The International Conference on Harmonization (ICH) final Concept paper on S7B and E14 Q&A (2018) also supports the use of human stem cell assays in preclinical safety screening Food and Drug Administration, HHS (2005). Additionally, a Ca^{2+} dye t assay to define the outcomes of the NCEs also showed consistency with findings in other well-established in vitro and in vivo cardiac risk assays.

Conclusion: Evaluation of a large list of reference compounds and internal NCEs has confirmed the applicability of the adaptations made to the previously published novel scoring system for the hiPSC-CMs. The validation also established the predictivity for drug-induced cardiac risks with good translation to other established preclinical in vitro and in vivo assays, confirming the application of this novel scoring system in different stem cell-CM lines for early cardiac hazard identification.

Keywords: stem cells, cardiomyocytes (hiPSC-CMs), cardiac hazard risk, HTS assay, translation
and TdP. We also investigated the translational value of the CTCM assay for prediction of liabilities in other established in vitro and in vivo nonclinical assays, e.g., hERG assay, isolated cardiac tissue (in vitro), and anesthetized guinea pigs (in vivo).

**METHODS**

The concept of cardiac hazard identification used in the current study was similar to the approach used earlier with the Cor.4u cell line (cardiomyocytes) (Kopijar et al., 2018b). In the present study, we used another cell line (iCell® Cardiomyocytes) to introduce the acute hazard score system to rank compounds based on the various parameters in the Ca²⁺ transient assay. (Figure 1).

**Cell Culture and Reagents for the Maintenance of hiPSC-CMs**

A commercially available hiPSC-CM cell line was used (iCell Cardiomyocytes²: Catalog number R1017, Kit/lot 12,012; Fujifilm Cellular Dynamics Inc., Madison, WI, United States) for the study. Cells were pre-plated and seeded in fibronectin-coated 96-well plates at a density suited to form a monolayer and maintained in culture in a stage incubator (37°C, 5% CO₂) according to the instructions of the cell provider. The experiments with test drugs were carried out 5–7 days after plating cells on the plate to have living, beating monolayer cardiomyocytes. The beating monolayer was taken from frozen vials iCell Cardiomyocytes² (∼5 million cells/vial), which were plated onto three 96-well plates (∼50K/well).

To investigate whether there could be lot-to-lot variability with hiPSC-CMs, we tested 55 drugs, known cardiac risks, in one lot of iCell Cardiomyocytes² (Lot 12,012), 19 common reference drugs in another lot of iCell Cardiomyocytes² (Lot105091) as well as in iCell Cardiomyocytes (Lot 103,674) (non-square cells). The experiments with test drugs were carried out 5-–7 days for iCell Cardiomyocytes² and 12–15 days (for iCell Cardiomyocytes) after plating cells to have living, beating monolayer cardiomyocytes (∼5 million cells/vial/96-well plates) (∼50K/well). Cells from these lot numbers were from the same donor (Apparently healthy...
normal, female, Caucasian, age <18) (according to FUJIFILM Cellular Dynamics).

**Calcium Transient Measurements**

The method for the Ca\(^{2+}\) transient assay used in the present study has been described previously (Zeng et al., 2016; Kopljar et al., 2018a; Kopljar et al., 2018b).

On the day of the experiment, the culture medium in the 96-well plates containing the monolayers of hiPSC-CMs was replaced with Tyrode’s solution (Sigma, No. T2397) supplemented with 10 mM HEPES together with KCl to yield isoosmotic (4.2 mM K\(^+\)) conditions.

The Ca\(^{2+}\)-sensitive fluorescence dye Cal-520™ AM (Cat. no.21131; AAT Bioquest) was used to capture the intracellular Ca\(^{2+}\) transients in hiPSC-CMs. The protocol used was as described in Kopljar et al. (2018a). Briefly, Cal-520 was incubated for 70 min followed by a wash-out with supplemented Tyrode’s solution and a 30-min recovery before starting the experiments at 37°C. On the day of the experiment, these solutions were further diluted with the supplemented Tyrode’s solution. Compounds were added automatically using the Functional Drug Screen System (FDSS/μCell; Hamamatsu, Japan) head stage by adding 100 µl of the 2-fold concentrated compound solution to wells with hiPSC-CMs already containing a volume of 100 µl of the experimental solution, reaching the final intended test concentration in 0.1% DMSO.

The spontaneous beating activity of hiPSC-CMs was assessed through measurement of the Ca\(^{2+}\) fluorescence signal integrated over the whole well. Ten minutes before starting the recordings, the experimental plates were put into the FDSS system for stabilization and a baseline recording was captured for 4 min followed by compound addition. The effect of the compounds was recorded around 30 min after compound addition. The Ca\(^{2+}\) transient signals were sampled every 16 ms (frame rate of 62.5 Hz) in hiPSC-CMs maintained at 37°C during the acquisition time. Calcium transient duration at 90% of repolarization (CTD90) is considered to be a surrogate for certain conduction block (Spencer et al., 2014). In addition, beat rate (BR = peak count/min) and amplitude (amp = difference between max. and min of every beat) were measured, and incidence of cellular arrhythmias, e.g., EAD-like activity (considered a surrogate of TdP), cessation of beating (~ stop beating), and below beating below quantification level (caused by low amplitude of the Ca\(^{2+}\) transient or by ectopic beat: BBQL) were also recorded (Figures 1B,C).

**Compound Selection, Drug Dilution, and Addition**

The compounds and their respective test concentrations were selected based on the CiPA compound list (Blinova et al., 2018 #240) and from our earlier publication (Kopljar et al., 2018b).

Four DMSO stocks for each drug concentration were prepared and either used on the same day or aliquoted and frozen. Concentrated (2-fold) testing solutions (50-fold for sequential dosing) for each concentration were prepared freshly on the day of testing by diluting DMSO stocks into the experimental medium. Two-fold dilution was done when drugs were added to the experimental well to achieve targeted concentration. For sequential dosing, DMSO concentrations were adjusted sequentially up to 0.1% at the highest concentration to achieve the targeted concentration of each drug. Each compound concentration was tested in 5-6 replicates.

Dofetilide (3 nM), isoprenaline (100 nM), and nimodipine (300 nM) were used as the positive controls, while cetirizine (300 nM) was used as the negative control. A total of 55 reference compounds were used in this study with different known clinical cardiac risks.

**Statistical Analysis for the Determination of the Score System**

For all individual experiments, delta percent (Δ%) at 30 min with respect to the baseline value was calculated [e.g., Δ% for CTD90 = (CTD90 30 min-CTD90 0 min)/CTD90 0 min] * 100]. The following two statistical approaches were used to make decisions about a compound’s effect.

First, the tolerance interval (TI)-based categorization, where the Δ% values of all (pooled) DMSO wells (experiments in this study) were centered around zero (corrected with the mean) and the parametric 90–95% (p = 0.90 & 1-α = 0.95) tolerance interval (TI) was calculated (Liao et al, 2005). TIs indicate an interval where, with a certain confidence level (1- α = 0.95), a specified proportion (p = 0.90) of a sampled population falls. The lower and upper limits based on the TI values were used as cut-offs for the vehicle-corrected net effect (ΔΔ%) values of the compounds to categorize them. These ΔΔ% net effects were the values obtained after normalization for baseline (Δ% vs. baseline) per well and the aggregated compound-treated wells are vehicle corrected by subtraction with the aggregated Δ% of the corresponding DMSO wells from the same plate [e.g., ΔΔ% = median Δ% drug - median Δ% DMSO]. The categorization was made first for each concentration and then aggregated per compound and test site. If a net effect (ΔΔ%) at a given concentration of a compound was below the lower limit of the TI, then it was categorized as “decreased”; if the net effect was within the DMSO TI then it was categorized as “no effect,” and if the net effect was above the upper limit of the TI then it was categorized as “increased.” At the compound level, a compound was categorized as “increased” if it was in a category “increased” in at least one of the four concentrations. Similarly, a compound was categorized as decreased if it was in a category “decreased” in at least one of the four concentrations. Based on TI values, we determined the cut-off values for the hazard score system (Kopljar et al., 2018b).

Data are expressed as means ± SEM. All statistical analyses were performed using SAS® software (Copyright© 2002–2012 SAS Institute Inc.).

**Sensitivity, Specificity, and Predictive Value of Potential Cardiac Risks in the Assay**

Significant prolongation of CTD90 observed in this assay was considered a surrogate for drug-induced QT prolongation and TdP risk. Since some drugs cause QT prolongation in humans at...
overdoses and/or in combination with other drugs, the predictivity values were calculated at free maximal plasma concentration in human (fC\text{max}) and also at a threshold of 10 X fC\text{max} or 30X fC\text{max}. The list of reference drugs that have QT-prolongation and potential risk for Tdp in humans was taken from the ParmaPendium® (www.pharmapendium.com) and from our recent publication (Kopljar et al., 2018b). A true positive (TP) was defined as QT-prolonging drugs that significantly prolonged CTD\text{90}, while true negative (TN) was defined as non-QT prolonging drugs in humans that did not prolong CTD\text{90} at a tested concentration. A false negative (FN) was defined as a known QT-prolonging drug that did not prolong CTD\text{90}, while a false positive (FP) was defined as a non-prolonging QT drug that significantly prolonged CTD\text{90} at >30-fold fC\text{max}. Sensitivity was calculated as the % of QT-prolonging drugs correctly predicted based on CTD\text{90} prolongation in this assay [TP/(TP + FN)]. Specificity was calculated as the % of non CTD\text{90} prolonging drugs correctly predicted as non-QT prolonging drugs [TN/(TN + FP)]. Positive predictive value (PPV) was calculated as: PPV = [TP/(TP + FP)], while negative predictive value (NPV) was NPV = [TN/ (TN + FN)].

Statistical Modeling of Drug Proarrhythmic Potential Based on its hiPSC-CMs Effects

The modeling used in this study was primarily based on the seven predictors from the measurement parameters in MEA as given in the CiPA publication (Blinova et al., 2018), with a slight modification. Data on effects of 55 drugs with known clinical risk of Tdp obtained from all experimental sites were used to construct a model that would predict Tdp risk category of a drug based on its effects on hiPSC-CMs. Seven modified endpoints from hiPSC-CM experiments used as potential model predictors (Blinova et al., 2018) were: Predictor 1, drug-induced cessation of beating and early afterdepolarization (EAD) at any concentration; Predictor 2, describes the ability of a drug to induce arrhythmia-like events (EAD) in over 40% of wells in hiPSC-CMs; Predictor 3, CTD\text{90} (ms) at the first drug concentration with statistically significant (p \leq 0.05) prolongation or shortening; Predictor 4, reflects the amount of drug-induced repolarization prolongation (CTD\text{90}% of baseline) at the lowest concentration where statistically significant change from the baseline was observed or maximum prolongation at any of the studied concentrations; Predictors 5 and 6, account for concentrations of a drug relative to its fC\text{max} when prolongation of CTD\text{90} or incidence of arrhythmia-like event was first observed; and Predictor 7, an estimated amount of CTD\text{90} prolongation that a drug would induce at its clinical fC\text{max}. We added predictor 8 that includes drug-induced cessation of beating in ≥40% of wells at any concentration, which added an extra value to detect drug-induced slow conduction time or inhibiting spontaneous beating.

Logistic regression models (Model 1 and Model 2) were then used (high or intermediate risk vs. low risk–Model 1, and high vs. low and intermediate-risk vs. low risk–Model 2) on all eight risk predictors according to the CiPA publication (Blinova et al., 2018).

Lot-to-Lot Variability

To investigate lot-to-lot variability in hiPSC-CMs, we tested 19 drugs with known clinical cardiac risk in other lots of iCell Cardiomyocytes. Fifty-five reference drugs were tested in iCell Cardiomyocytes1-Lot12012, 18 reference drugs were tested in iCell Cardiomyocytes2-Lot105091, and 18 reference drugs were tested in iCell Cardiomyocytes (Lot103674) (nonsquare cells).

Comparison of Outcomes Between the Current CTCM Human Assay in hiPSC-CMs (iCell-Cardiomyocytes2) and the Earlier Stem Cell-Derived Cardiomyocytes (Cor.4u2 Cardiomyocytes)

To investigate the reproducibility of the cardiac hazard risk predictions from the different cell lines, we compared the present data with the results of 55 reference drugs obtained from hiPSC-CMs (iCell Cardiomyocytes2) to the data obtained from another cell line which was published previously (Kopljar et al., 2018b).

Evaluation of the Translatability of the Scored Hazard Potential of NCEs in the Calcium Transient Assay in hiPSC-CMs to Other Nonclinical in Vitro and in Vivo Cardiac Safety Assays Including Animal Models

We also evaluated the translational predictability of the risk scores of NCEs in the CTCM assay to our complementary cardiac safety models: hERG assay, isolated rabbit wedge preparation (ex vivo) (Lu et al., 2016), and anesthetized guinea-pig (in vivo) models (Kopljar et al., 2018b) using the Software - SPEcII (Unlimit-IT, Belgium). All the experiments involving the use of animals have been conducted in accordance with “The provision of the European Convention” on the protection of vertebrate animals that are used for experimental and other scientific purposes, https://rm.coe.int/168007a67b.

RESULTS

Acute Cardiac Hazard Scoring System

We applied our previously reported strategy and methodology for the development of a cardiac hazard scoring system based on phenotypic readouts from Ca\textsuperscript{2+} transient imaging to a different hiPSC-CM cell line (iCell Cardiomyocytes2) (Figure 1A). For a qualitative evaluation of hiPSC-CMs, each test plate (i.e., 96 unique experiments) contained 0.15 DMSO controls, together with several control drugs (cetirizine, isoprenaline, nimodipine, and dofetilide). These drugs have different pharmacological classes and were served as a pharmacological reference set for
FIGURE 2 | Determination of Cutoff Values Using Statistical Tolerance Intervals (TIs) to Build a Hazard Scoring Matrix. The TIs (dashed lines within graphs) for vehicles and positive controls to determine bidirectional cutoffs for CTD90 to be mild or strong effects (Panel A), BR (Panel B), and Amp (Panel C). TIs from vehicle (n = 368) were applied to define the “no effect” cutoffs as well as the cut-off between “no effect” and “mild effect.” Panel (A): Nimodipine (300 nM; n = 173) and dofetilide (3 nM; n = 178) were used to determine “strong” CTD90 shortening and prolongation cut-offs, respectively. Panel (B): Isoprenaline (100 nM; n = 171), and 0.1% DMSO (n = 368). TIs were used to define “strong” BR increase. Panel (C): Nimodipine and isoprenaline were used to define “strong” amplitude decrease and increase, respectively. Tolerance intervals (Δ%) were corrected for vehicle offset to determine the cut-offs (ΔΔ%). Panel (D): Scoring points for hazard score identification: The scoring matrix shows a points card where for each parameter a weighted score is given depending on the size and direction of the ΔΔ% effect. Panel (E): Calculation of hazard level based on the sum of points across all parameters. Panel (F): Pie charts showing the scoring of various reference drugs over multiple studies. Cetirizine (3 μM; n = 104), isoproterenol (100 nM; n = 143), nimodipine (300 nM; n = 124), doxetilide (3 nM; n = 131). n indicates the number of studies; each study contained 4–8 individual experiments.
FIGURE 3 | Evaluation of reference drugs for cardiac hazard. Fifty-five reference drugs were scored for cardiac hazard using the scoring matrix. “Known TdP”, “conditional TdP”/potential TdP groups show the marketed medicine containing these warnings in their FDA label, as well as some reference drugs that are known to block Na+ channels, shorten QT, or have other mechanisms acting on cardiac receptors or other ion channels. Concentrations were tested according to the therapeutic fCmax (shown in italics), as described in our previous publication (Kopljar et al., 2018b). n. a, not available.
The development of the hazard scoring system. Cetirizine is a real negative control known not to have any clinical cardiac liabilities. Nimodipine was used as a calcium channel antagonist and isoprenaline is a beta-adrenergic agonist. Dofetilide is a hERG blocker associated with QT prolongation and proarrhythmic TdP risk in humans. Pharmacological effects in hiPSC-CMs were investigated after a 30-min incubation period and normalized against the respective baseline recording, yielding a Δ% change in CTD90, BR, and Amp.

The current hazard scoring outcome was largely similar to our previously reported scoring system for the Cor.4u cell line (Kopljari, 2018 #245, based on the TIs and its modified cut-off values of key parameters: CTD90, beat rate, amplitude, and incidence of arrhythmic events (EAD and cessation of beating). The scoring matrix was determined based on the cut-offs between the different effect zones for each parameter (Figure 2). The “no effect” zone shows minimal changes in a parameter that is within vehicle variability, whereas “mild” and “strong” zones are determined from mild to large changes bidirectionally (e.g., CTD90 shortening and prolongation). The cut-off values are net changes (ΔΔ% changes vs. baseline and vehicle), which are based on the statistical tolerance intervals (TIs) (Δ% changes vs. baseline). TIs indicate an interval where, with a certain confidence level, a specified proportion of a sampled population falls. Vehicle treatments showed low variability in Δ% change for CTD90, BR, and Amp with respect to baseline (Figure 2). Cardiac hazard scoring for the tested compound at a given concentration was given into the following risk classification hazard score (color labels): “No” (green), “Low” (yellow), “High” (red), and “Very High” (black). No hazard labeling means that a tested compound’s effects were within the vehicle variability. Low hazard score indicates that the effects were outside the vehicle variability, with = low or limited risk. High hazard score gives a strong concern whereas the very high hazard score suggests potentials to cause cardiac arrhythmias-EADs.

**Investigation of the Hazard Scoring System**

Based on the outcomes of the positive/negative controls and the reference drug list used in another cell line (Cor.4U) (Kopljari, 2018 #245), we validated the results in this new hiPSC-CM cell line (iCell Cardiomyocytes) which was essential for using the scoring system for hazard identification of NCEs. Figure 2F shows the hazard distribution for control drugs (at a single concentration) tested in numerous studies. Cetirizine at 1 μM (16-fold the fCmax) as a negative control was exclusively identified to be a no hazard agent. Nimodipine at 300 nM (15-fold fCmax) (n = 124) and isoproterenol (n = 143) at 100 nM (63-fold fCmax) are both cardio-active agents that were identified within the low and high hazard zones (95 and 92%, respectively). Dofetilide at 3 nM (2-fold fCmax) (n = 131) was correctly identified as yellow (8%), high (red color) (21%), or very high (black color) (71%) hazard score.

Following up, we validated the hazard scoring (as defined in Figure 3) using 55 reference drugs and their respective known clinical risk relative to their fCmax. These reference drugs are categorized based on their pharmacological mechanism or level of cardiac side effects in men (Figure 4). Indeed, negative control drugs have no reports of cardiac liabilities in humans and are expected to be proven to be “no hazard” for concentrations up to 10- to 30-fold fCmax. All negative controls were found to have “no hazard” (green). The only special case was raloxifene at clinically irrelevant concentrations (3–10 μM; ≥2500-fold the clinical fCmax).

We investigated the potential hazard scoring system for drugs, known to be associated with QT prolongation and a certain degree of TdP risk in humans (Figure 3) (These drugs were categorized into two groups according to the FDA label or described in www.torsades.org: conditional TdP/potential TdP risk, and known TdP incidence. In cases of overdose, drug–drug interactions, or in certain high-risk individuals (Woosley et al., 2018). The rank order of
incidence of EADs or degree of prolongation of CTD_{90} could be found to be co-related well to known TdP drugs > potential TdP risk or “Conditional TdP risk.” Only the antidepressant olanzapine was not found to be with any hazard level, most likely because of the fact that the highest tested concentration was 100 nM, which is around fC_{max}. This concentration might be too low, since olanzapine was also only found to significantly inhibit HERG at a concentration of 6 µM, which is at 90-fold fC_{max} (Titier et al., 2005).

Although the main focus within preclinical safety pharmacology in most pharmaceutical companies is on drug-induced QT prolongation and TdP, other pharmacological mechanisms affecting different cardiac ionic currents can also result in cardiac toxicity such as, e.g., QRS widening or QT shortening. Na⁺ channel blockers such as primidone and phenytoin, which are considered relatively safe in humans, had little impact on hiPSC-CMs (Green score) and another Na⁺ channel blocker, mexiletine, caused some cessation of beating only at a very high concentration (100 µM = 67x fC_{max}), resulting in a Red score in the current study, similar to that in the CIPA validation study (Blinova et al., 2018). However, most Na⁺ blockers also inhibit hERG current at similar concentrations, which are readily detected as CTD_{90} prolongation and incidence of EADs leading to “low” to “very high” risk (Figure 3).

Ca²⁺ channel antagonists resulted in strong responses in hiPSC-CMs, showing a marked decrease in amplitude accommodating with CTD_{90} shortening and pronounced beat rate increase. The cardiac IK_{ATP} channel opener and the hERG activator (ICA-105574), which shortened CTD_{90} were also characterized in the present study.

Additional pharmacological mechanisms including beta-adrenergic agonists (isoproterenol, dobutamine, and salbutamol), Na⁺/K⁺ ATPase inhibitors (digoxin and ouabain), calcium channel activator (BAYK8644), and a nonselective 5-HT_{4} agonist (tegaserod), were withdrawn from the market Na⁺ channel blockers such as primidone and phenytoin, which are considered relatively safe in humans, had little impact on hiPSC-CMs (Green score) and another Na⁺ channel blocker, mexiletine, caused some cessation of beating only at a very high concentration (100 µM = 67x fC_{max}), resulting in a Red score in the current study, similar to that in the CIPA validation study (Blinova et al., 2018). However, most Na⁺ blockers also inhibit hERG current at similar concentrations, which are readily detected as CTD_{90} prolongation and incidence of EADs leading to “low” to “very high” risk (Figure 3).

Ca²⁺ channel antagonists resulted in strong responses in hiPSC-CMs, showing a marked decrease in amplitude accommodating with CTD_{90} shortening and pronounced beat rate increase. The cardiac IK_{ATP} channel opener and the hERG activator (ICA-105574), which shortened CTD_{90} were also characterized in the present study. Additional pharmacological mechanisms including beta-adrenergic agonists (isoproterenol, dobutamine, and salbutamol), Na⁺/K⁺ ATPase inhibitors (digoxin and ouabain), calcium channel activator (BAYK8644), and a nonselective 5-HT_{4} agonist (tegaserod), which were withdrawn from the market due to adverse cardiovascular events, were also validated in the present study and showed similar acute hazard scoring outcome as determined in Cor.4U cell line. As expected, BaCl₂ (an IK_{1} inhibitor) had no effect on hiPSC-CMs since it is known that most current commercial hiPSC-CMs lack functional IK_{1} channels (immature phenotype) (Goversen et al., 2018; Pourrier and Fedida 2020). Similarly, IK_{1} inhibitor (JNI-303) was not detected in hiPSC-CMs (Kopjar, 2018 #245).

In the previous score system with Cor.4U cell line (Kopjar et al., 2018b), significant drug-induced decrease in beat rate did not significantly impact hazard score because the maximal decrease in beat rate was only adding 5 points while the threshold for the minimal hazard score (Yellow; low risk) was 10 points. In the current updated scoring system, significant decreases induced by the muscarinic acetylcholine receptor M_{4} agonist (carbachol), adenosine receptor agonist (adenosine), and funny channel current (I_{f}) inhibitor (ivabradine) were identified as potential “low” risk (Yellow) by adding 10 points for the decrease in beat rate by ≥ −30% (delta/ delta from baseline and 0.1% DMSO control) (Figure 4). With this update in the scoring paradigm for changes in beat rate, we identified 29 out of ~3,000 screened reference and proprietary compounds that decreased beat rate by ≥ 30%. These 29 compounds include carbachol, adenosine, zatebradine, ivabradine, arecoline, methacholine, ibutilide, flecaainide, and other internal NCEs.

**Lot-to-Lot Variability**

To investigate the lot-to-lot variability in responses/scores of hiPSC-CMs provided by the vendor, some of the reference drugs that prolong QT and/or have TdP risks (total of 19 compounds) were tested in different lots.

The mean baseline Ca²⁺ transient parameter values were amplitude (3,470, 2,854, and 2017 RLU), beat rate (28, 26, and 34 beats/min), and CTD_{90} (947, 1,006, and 790 ms) for lot 12,012 (iCell Cardiomyocytes²) (n = 2,463), lot 105091 (iCell² Cardiomyocytes²) (n = 521), and lot 103674 iCell Cardiomyocytes) (n = 400), respectively. There were no incidences of EADs or cessation of beating at baseline. The responses to the positive controls (isoproterenol, nimodipine, and dofetilide) and the negative controls (cetirizine or DMSO) were qualitatively similar among the three lots. For example, dofetilide (3 nM) prolonged CTD_{90} by 30% in lot 12,012 (n = 144), 330% in lot 10,591 (n = 28), and 234% in lot105091 (n = 20), and incidence of EADs was similar among the two iCell Cardiomyocytes² lots and the iCell Cardiomyocytes: 63, 71, and 65% incidence of EADs, respectively.

Responses to three drugs that do not prolong QT or have no TdP risk (captopril, ebastine, atenolol) were similar among the iCell Cardiomyocytes² and iCell Cardiomyocytes² lots: “no hazard”/green color, Figure 4). Interestingly, the cardiac risk scores for 10 drugs known to prolong QT and induced TdP were also similar in two lots of iCell Cardiomyocytes² and iCell Cardiomyocytes. However, EAD incidence for dl-sotalol was much higher in iCell Cardiomyocytes (10 µM) compared to the two lots of iCell-Cardiomyocytes (3 and 10 µM). Five reference drugs with other mechanisms of acute cardiac risk (hERG activator, IK_{ATP} channel opener, Ca²⁺ antagonist, and Na⁺ channel blockers) were also similar among the three lots with slight variations acceptable for any in vitro assay (Figure 5).

**Analysis of Sensitivity, Specificity, and Predictivity Values**

We analyzed the potential acute cardiac risks of 55 reference drugs with known degrees of risk in humans using the current hazard scoring system based on changes in beat rate, amplitude, CTD_{90}, and incidence of arrhythmias. We compared the cardiac risk of these 55 reference drugs based on our scoring system to the potential for clinical QT-prolongation/TdP risk, QT-shortening, QRS-prolongation, or all potential cardiac arrhythmias (i.e., non-TdP like VT/VF, bradycardia, etc.). Based on the numbers of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN), we calculated sensitivity (TP/(TP + FN)), specificity (TN/(TN + FP)), and balanced accuracy (TP + TN). In summary, the total cardiac risks prediction was at 95%: 10 no cardiac risk drugs were all negative (green score), and for QT-prolongation/TdP risk on this CTCM assay with a balanced predictivity of 90%, sensitivity of 85%, and 95% specificity (Figure 6). FP was at 0 out of 43 while FN was at 2 out of 12 compounds (BaCl₂ and JNI-303: experimental drugs).
Comparison of the Acute Cardiac Hazard
Cardiac Risks Between the Current Cell Line-hiPSC-CMs (iCell Cardiomyocytes2) and Cor.4U Cell Line in the Ca2+ Transient Assay

Fifty-five reference drugs were tested in iCell Cardiomyocytes2 in the current study and compared to Cor.4U in the CTCM assay (Kopljar et al., 2018b). The acute cardiac hazard scores of these 55 reference drugs were similar between the 2 cell lines. The prediction values of acute cardiac risk and QT prolongation/TdP risk in both cell lines were >90% (Figure 5A). When taking into account the fold over its fCmax (Figure 7B): <10 -fold fCmax: the predictive value with the Cor.4u cell line was slightly higher, and at <30 or <100 -fold fCmax, the iCell Cardiomyocytes2 had slightly higher predictive values compared with the Cor.4u cell line. However, both cell lines were equal in defining cardiac risks in general.

Statistical Modeling of Drug Proarrhythmic Potential

In addition, we used statistical modeling of proarrhythmic potential for the 55 drugs with known clinical risk for QT-prolongation and TdP based on the results from CTCM assay and hazard scoring system. Eight endpoints from the CTCM assay were used for potential mode predictors that include seven predictors defined in the CiPA publication ((Blinova et al., 2018)), and an additional predictor: cessation of beating was included (Lu et al., 2019): Predictors 1 and 2 indicate a test drug that elicited an arrhythmia-like event (i.e., early afterdepolarization: EAD): Predictor 1 (binary): did any drug induce EAD at the tested concentration [0 = no EAD; 1 = EAD]); Predictor 2 (binary): EAD...
observed at any concentrations in $\geq 40\%$ wells ($0 = \text{no}; 1 = \text{yes}$); Predictor 3: first drug concentration with statistically significant ($p \leq 0.05$) prolongation or shortening of repolarization; Predictor 4: defined the maximal drug-induced changes in repolarization (CTD$_{90}$) observed at any concentration; Predictor 5: defined drug concentration (multiple of fC$_{\text{max}}$) at the first statistically significant ($p < 0.05$) prolongation of CTD$_{90}$; Predictor 6: accounted for the first drug concentration relative to its clinical fC$_{\text{max}}$ to induce EAD; Predictor 7: had drug-induced changes in CTD$_{90}$ (ms) at $\sim$ its free C$_{\text{max}}$; Predictor 8 (binary): caused cessation of beating at any concentration in $\geq 40\%$ of wells ($0 = \text{no}; 1 = \text{yes}$).

As described in the CiPA publication, two logistic regression models for the potential TdP risk group were used: Model 1: had high or intermediate risk vs. low risk and Model 2: had high risk vs. low risk and intermediate risk vs. low risk.

The results of the 55 reference drugs including a large set of CiPA compounds in the statistical model are shown in Figure 7. The models predicted well for high- and intermediate-risk drugs as well as for low-risk drugs with identified incidence in humans. There were very limited drugs overlapping between the intermediate- and low-risk drug (e.g., raloxifene). However, the concentrations used in the study were substantially higher compared with its fC$_{\text{max}}$ in humans (1.2 nM). Raloxifene is a selective estrogen receptor modulator that is used for women with postmenopausal osteoporosis and is not associated with QT-prolongation in clinic. Raloxifene was reported to inhibit I$_{\text{Kr}}$ with an IC$_{50}$ at 1.1 µM and I$_{\text{Ks}}$ with an IC$_{50}$ at 4.8 µM, and voltage-gated Na$^+$ current with an IC$_{50}$ at 2.8 µM (Liu et al., 2010). This may explain the identified activity in the current assay at much higher concentrations compared with free C$_{\text{max}}$ (>1,000 fold its C$_{\text{max}}$) that could be associated with some risk for QT-prolongation.

**Assessment of the Hazard Potential of NCEs**

Sequentially, we investigated 839 NCEs including Janssen discovery research projects based on molecules (Figure 8A). Compounds were tested at a wide concentration range (0.1–10 µM). Hazard evaluation identified that the most of NCEs were classified within the “no hazard” group at concentrations less than 10 µM, with a portion showing risk at the highest concentration of 10 µM. 839 NCEs (54%) were found to be no hazard over the entire tested concentration range. Additionally, for compounds with identified hazard, the levels increased in a concentration-dependent manner. At 1 µM and higher, over 50% of the compounds did show some effects associated with a certain hazard level in hiPSC-CMs, with the “high hazard” mainly at 10 µM. The proportion in the “very high” compounds, linked to arrhythmic-like EADs, was relatively small at 10 µM with some incidence also observed at lower concentrations.

Although the hazard score classification is used as an initial indicator for potential for cardiac toxicities, further analysis in other models is necessary to help to better understand the pharmacological mechanisms involved, ultimately leading to a comprehensive integrated hazard identification. Therefore, we separated the low from high hazard groups (at 1, 3, and 10 µM) in terms of the directional effect on CTD$_{90}$ (Figure 8B). CTD$_{90}$ prolongation was mainly cause of hazard labeling among compounds for all hazard-concentration combinations (Figure 8B). At 1 and 3 µM, high hazard identification was mostly caused by CTD$_{90}$ prolongation, and by the combination of CTD$_{90}$ prolongation and beat stop (cessation of beating) at 10 µM.

**Translational Value of CTCM Human Assay Compared to hERG and QT Assessment**

A sum of 121 compounds were tested in both the hERG patch-clamp and CTCM assays at the similar concentration ranges (Figure 8C). There were 66 compounds with no risk in the CTCM assay: 53 out of 66 compounds showed hERG inhibition ≥25% while 13 of 66 compounds showed no effect in the hERG assay. There were 55 of 121 compounds that had low to very high hazard score in the CTCM assay, and only 5 of these 55...
FIGURE 8 | Hazard score investigation using the scoring system on Janssen NCEs in early R&D. (A) Pie charts showing the concentration-dependent distribution of different hazard score levels ($n = 839$). (B) Detailed analysis of proportion of effects on $\text{CTD}_{90}$ (increase or decrease) and incidence of beat stop (BS) or fibrillation in low and “high risk” categories by concentration (1, 3, and 10 µM) on CTCM assay. Panels (C–E): The outcome of acute cardiac hazard scores in CTCM assay was compared to the inhibition among 121 compounds in the hERG assay (Panel C), to the effects on QT interval or QRS duration among 73 compounds in isolated rabbit ventricular wedge assay (Panel D), and to the effects on QTcB interval and QRS duration among 26 compounds in anesthetized guinea-pigs (Panel E). In Panel D, the left side pie: labeled Overall: including effects on both QT interval and QRS duration on a total of 73 compounds. In Panel E, the left side pie: labeled Overall: including effects on both QTcB interval and QRS duration on a total of 26 compounds. Confirmed: matching outcome between the two assays. Not Confirmed: not matching outcome between two assays.
compounds (9%) showed no effect in the hERG assay, while 50 of 55 compounds (91%) were confirmed active in the hERG assay, indicating that the drug-induced hazard scores were primarily due to inhibition of hERG current. The difference between the CTCM assay and the HERG assay could be caused by the effects on the CTCM assay not only mediated by affecting HERG current but also on other cardiac ion channels/receptors, or due to small % of false positive and negative on HERG assay.

Seventy-three compounds (acute hazard scores from the CTCM assay) were also tested in the isolated rabbit ventricular wedge preparation (Figure 8D). From 52 of these 73 compounds that had hazard scores in the CTCM assay, 96% (50 out of 52 compounds) had effects on either QT interval or QRS or both QRS and QT-interval in the isolated rabbit wedge assay, while only two (4%) had no effects on QRS or QT-interval in the isolated wedge preparation. Of the 21 of 73 compounds that had no hazard score in the CTCM assay 43% (9 of 21 compounds) were confirmed to have no effects in the isolated rabbit wedge preparation while 57% (12 of 21 compounds) had effects on QT interval and/or QRS: 8 compounds had QT effects; 3 had both QT and QRS effects, and 3 widened only QRS duration. However, the effects of these compounds on QT interval and QRS duration in the wedge preparation were relatively small.

Twenty-six compounds that had hazard scores in the CTCM assay were also tested in anesthetized guinea pigs (in vivo) (Figure 8E): Of the compounds that had no risk (green) in the CTCM assay, eight were also found to have no effects in anesthetized guinea-pigs in terms of changes in QRS duration and QTcB interval. One compound (terfenadine) slightly shortened CTD90 and caused cessation of beating in the CTCM assay, but significantly prolonged QRS duration and QTcB interval in the anesthetized guinea pig at much higher plasma levels than that of the CTCM assay. Terfenadine is known to have solubility issues in vitro and possibly resulting in less than nominal concentrations in the CTCM assay (Lu et al., 2012). In addition, terfenadine is rapidly metabolized in the liver to an active metabolite. Of seventeen compounds that scored yellow/red/black risk hazard scores in the CTCM assay, 71% were confirmed as positive in the anesthetized guinea pig. However, 29% of these 17 compounds (5 of 17 compounds) did not have significant effects in anesthetized guinea pigs in terms of changes in QRS duration and QTcB interval. Explanations for some of these discrepancies include: One compound slightly shortened CTD90 and tended to shorten QTcB interval in vivo; the free plasma levels of another four compounds (high plasma protein binding in vivo) were much lower than in the CTCM assay.

**DISCUSSION**

Human stem cell-derived CMs are now applied to evaluate cardiac liabilities as part of early de-risking in drug research and development (R&D). In our earlier publication ((Kopljar et al., 2018b)), we introduced a hazard scoring system to aid in the selection of new chemical entities (NCEs) devoid of acute cardiac risks. In the present study, we successfully applied the same principles of the previous hazard score system to a different hiPSC-CM line (iCell Cardiomyocytes^2), using statistical TI (s) and cut-off values for the key parameters from Ca^{2+} transient fluorescence recordings, based on DMSO controls and a validation set of 55 clinically known reference drugs that included positive and negative controls for various parameters. Statistical analysis (tolerance intervals) on a large historical data set of vehicles and control drugs helped the development of a detailed scoring system with differentiation of size and direction of effect for each parameter. We documented and confirmed the utility of various parameters [(CTD90, beat rate, amplitude, cessation of beating, BBQL, fibrillation-like event and EADs), measured in spontaneously beating hiPSC-CMs to generate a hazard identification score from data of the different pharmacological classes of drugs. To our knowledge, this is a more extensive approach relative to most other studies using hiPSC-CMs, where the focus is exclusively on APD-related parameters (e.g., field potential duration or CTD90) associated with changes in the QT interval. The hazard coring system, based on the measurement of a Ca^{2+} transient in hiPSC-CMs (CTCM), can help detect and define cardiac hazards beyond drug-induced QT prolongation, such as QT shortening, beating rate changes, and slowing of conduction. This hazard score system can also identify potential hazards of drug-induced significant decreases in beating rate mediated by mechanisms such as muscarinic acetylcholine receptor M2 stimulation (carbachol), adenosine receptor agonist (adenosine), and I_f inhibitor (ivabradine), which was lacking in our previous hazard scoring system derived from Cor.4U-cell line (Figure 8). With the newly updated hazard score system, by adding an extra 5 points to the risk score for drug-induced decrease in beat rate (total 10 points for decreases in rate by ≥30%), we now are able to identify this additional hazard as a low hazard score (Yellow) in 2.9% of 3,019 NCEs tested in this cell line. We have used the hazard scoring system to simplify the analysis of complex drug-induced effects on hiPSC-CMs and provide a scoring system to identify and select safe NCEs facilitating the progress of these molecules in early R&D. Interestingly, a decrease in beat rate ≥30% has limited propensity to prolong CTD90 (Figure 4): The prolongation of CTD90 is still within the cut-off values of DMSO controls in these cases, which indicates that the rate dependence of CTD90 in this in vitro assay is not the same as in vivo, where QT interval must generally be corrected for heart rate.

The discovery and development of novel NCEs is a long and expensive process, and there is a considerable rate of attrition resulting in part to a safety concern. Therefore, an in vitro assay capable of detecting safety issue early in discovery and development, particularly cardiac safety, is crucial for optimized candidate selection and reduction of human risk in clinical trials and with drugs approved for use in patients. This assay and the scoring system defined and described in this study can be readily applied to select the best drug candidates based on safety.

Our validation set of 55 reference drugs included the large set of GIPA compounds, used in the FDA/HESI (Blinova et al., 2018) and JiCSA (Kanda et al., 2018) studies, and showed comparable risk assessment. The models were highly predictive for high- and intermediate-risk drugs as well as for low-risk drugs, based on known risks in humans. There were a few apparent examples of
inconsistency between risk scores in the CTCM and level of risk in humans (e.g., raloxifene). Raloxifene is a selective estrogen receptor modulator that is broadly used in the treatment of postmenopausal osteoporosis and known to not prolong QT interval at therapeutic doses. In the present study, the concentrations of raloxifene used were higher than that of its \( \text{IC}_{\text{max}} \) in humans (1.2 nM). Raloxifene presented with a high hazard score (high risk) but this was only observed at >2000 folds of its \( \text{IC}_{\text{max}} \). At ~700–800 folds \( \text{IC}_{\text{max}} \) raloxifene had a green score (low risk), consistent with its clinical safety profile. Raloxifene has been reported to inhibit cardiac delayed rectifier \( K^+ \) currents at high exposures (\( I_{\text{IC50}} \) \( \text{IC}_{50} = 1.1 \) \( \mu \)M and \( I_{\text{Ks}} \) \( \text{Ks} = 4.8 \) \( \mu \)M), which may explain the high hazard score and potential for QT prolongation at >2000 folds its \( \text{IC}_{\text{max}} \).

Importantly, we also documented that there was very little lot-to-lot differences in hazard results for 19 common reference drugs in iCell Cardiomyocytes\(^2\) (two lots) and iCell Cardiomyocytes (one lot).

Additionally, the specificity, sensitivity, and predictivity values for the cardiac risk assessment of 55 reference drugs were very high (>95%). The functional output of the current platform using \( \text{Ca}^{2+} \) transients enabled phenotypically relevant readouts of acute cardiac risk \textit{in vitro}. The hazard scoring system predicted potential for long QT/TdP risk of 55 reference drugs as well as total cardiac risks (drug-induced short QT and VF-like) with over 95% specificity, sensitivity, and total balanced cardiac risk when compared with the known risk in humans. Importantly, the hazard scoring system predicted the cardiac risks of the 55 reference drugs mostly within the range of therapeutically relevant free plasma concentrations (\( \text{IC}_{\text{max}} \)) (Figure 6). The set of 55 reference drugs in the study covered a broad range of different drug classes with different pharmacological mechanisms that include both cardiovascular and noncardiovascular drugs. Using such a large set of reference drugs we were able to establish a hazard scoring system that can be applied in the selection of safe NCEs early in the drug discovery process. Although a threshold of >10- (>30- or ≤100-fold) \( \text{IC}_{\text{max}} \) was used for analyzing the scoring and assessing the predictivity of the assay, it should be noted that in many \textit{in vitro} assays concentrations up 30-fold \( \text{IC}_{\text{max}} \) are normally considered relevant for predicting cardiac effects in humans (Redfern et al., 2003). In both the present and the CIPA stem cell validation study (Lu et al., 2019), four concentrations were used to capture \( \text{IC}_{\text{max}} \) levels with 10- and 30-fold \( \text{IC}_{\text{max}} \) margins. Additionally, cardiac and noncardiac drugs including disopyramide, terfenadine, diphenylhydramine, domperidone, fluoxetine, and sertindole, etc., are known to have functional cardiac effects \textit{in vitro} assays at much higher concentrations than their \( \text{IC}_{\text{max}} \) level (>30–100 folds \( \text{IC}_{\text{max}} \) (Redfern et al., 2003). (Pacher et al., 2000; Eckardt et al., 2002).

To add value and gain confidence to the predictions and compound selection, screening results in this novel assay and scoring system for cardiac safety also need to be consistent with existing established early nonclinical screening assays, as well as more complex follow-up preclinical assays. Therefore, we evaluated the translational value of the current assay compared with other \textit{in vitro} assays (such as the hERG current assay and the \textit{ex vivo}-isolated rabbit left ventricular wedge preparation, as well as the anesthetized guinea-pig model, an established sensitive \textit{in vivo} model to detect electrocardiographic risk (Testai et al., 2004; Lu et al., 2016)). The scoring system validation in the CTCM assay, based on reference and internal proprietary compound evaluation, was largely consistent with hERG assay results in terms of CTD\(_{90}\) prolongation, despite some false positives and negatives, as might be expected for compounds with more complex electrophysiological actions. The scoring outcome from the CTCM assay was also largely confirmed in anesthetized guinea pigs and the isolated rabbit wedge ventricular preparation (Figures 8C–E).

The scoring system that we developed provides a reliable way to readily identify the concentration-dependent level of cardiac risk by concentration for NCEs based on \( \text{Ca}^{2+} \) transient measurement in hiPSC-CMs using multiple functional parameters including beat rate, CTD\(_{90}\), and amplitude. However, despite the great promise of the current scoring system for predicting acute cardiac risks, a few limitations still exist. Similar to other \textit{in vitro} assays, the current HTS assay does not detect potential effects of active drug metabolites, which would only be detected in an \textit{in vivo} study or by directly testing the known active metabolite in the current assay. Poor solubility may also be an issue. Moreover, similar to any \textit{in vitro} assay using hiPSC-CMs, these cells are not fully matured, although they express key cardiac genes and have comparable function of most cardiac ion channels and receptors, and this might influence the responses to some drugs in hiPSC-CM line. That could cause difference between hiPSC-CMs and isolated cardiac tissue assays.

Our current model validation data with 55 reference drugs showed predictions of drug-induced cardiac hazard score in hiPSC-CMs (iCell-Cardiomyocytes\(^2\)) that were found to be similar to those in another cell line (Cor.4U Cardiomyocytes) (Kopjar et al., 2018b), indicating the adaptability and consistency of our scoring system approach. Screening of drug-induced effects in hiPSC-CMs can also be performed using different detection technologies, e.g., measurements of extracellular field action potentials (Ando et al., 2017), impedance/MEA (Zhang et al., 2016; Bot et al., 2018), video motion imaging (Hayakawa et al., 2014), and voltage-sensitive dyes (Bedut et al., 2016). The principles used for the development of our scoring system could also be adapted for use in these other human cardiomyocyte systems using the same principles defined within this study.

In conclusion, the acute cardiac hazard score system applied to the \( \text{Ca}^{2+} \) transient assay using different hiPSC-CM cell lines should be useful for the identification and selection of NCEs for further investigation. The CTCM HTS assay system in our hands is user-friendly, and relatively inexpensive.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the cell line from human Stem cells is from
commercial provider. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

**AUTHOR CONTRIBUTIONS**

All authors are employed at [NJ]: HL is the first author (study design, data analysis, and wrote manuscript), MK and VK were responsible for data analysis, FT was responsible for TI and statistical modeling, DG performed experiments, AT and DG provided scientific supports. All authors agreed to be accountable for the content of the manuscript.

**REFERENCES**

Ando, H., Yoshinaga, T., Yamamoto, W., Asakura, K., Uda, T., Taniguchi, T., et al. (2017). A New Paradigm for Drug-Induced Torsadogenic Risk Assessment Using Human iPSC Cell-Derived Cardiomyocytes. *J. Pharmacol. Toxicol. Methods* 84, 111–127. doi:10.1016/j.vascn.2016.12.003

Author, S., Puglsey, M. K., Koerner, J. E., Ferrini, B., Redfern, W. S., Valentin, J.-P., et al. (2017). Proarrhythmia Liability Assessment and the Comprehensive In Vitro Proarrhythmia Assay (CiPA): An Industry Survey on Current Practice. *J. Pharmacol. Toxicol. Methods* 86, 34–43. doi:10.1016/j.vascn.2017.02.021

Bedut, S., Senninatore-Nole, C., Lamamy, V., Caignard, S., Boutin, J. A., Nojean, O., et al. (2016). High-throughput Drug Profiling with Voltage- and Calcium-Sensitive Fluorescent Probes in Human iPSC-Derived Cardiomyocytes. *Am. J. Physiology-Heart Circulatory Physiol.* 311 (1), H44–H53. doi:10.1152/ajpheart.00793.2015

Blanchette, A. D., Grimm, F. A., Dalaijamts, C., Hsieh, N.-H., Ferguson, K., Luo, Y.-Blinova, K., Dang, Q., Millard, D., Smith, G., Pierson, J., Guo, L., et al. (2018). Bootman, M. D., Allman, S., Rietdorf, K., and Bultynck, G. (2018). Deleterious Colatsky, T., Fermini, B., Gintant, G., Pierson, J. B., Sager, P., Sekino, Y., et al. (2016). Bedut, S., Seminatore-Nole, C., Lamamy, V., Caignard, S., Boutin, J. A., Nosjean, O., et al. (2016). High-throughput Drug Profiling with Voltage- and Calcium-Sensitive Fluorescent Probes in Human iPSC-Derived Cardiomyocytes. *Am. J. Physiology-Heart Circulatory Physiol.* 311 (1), H44–H53. doi:10.1152/ajpheart.00793.2015

Bootman, M. D., Allman, S., Rietdorf, K., and Bultynck, G. (2018). Deleterious Colatsky, T., Fermini, B., Gintant, G., Pierson, J. B., Sager, P., Sekino, Y., et al. (2016). International Multisite Study of Human-Induced Proarrhythmic Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment. *Cell Rep.* 24 (13), 3582–3592. doi:10.1016/j.celrep.2018.08.079

Boothman, M. D., Allman, S., Riedolf, K., and Bultynck, G. (2018). Deleterious Effect of Calcium Indicators within Cells; an Inconvenient Truth. *Cell Calcium* 73, 82–87. doi:10.1016/j.ceca.2018.04.005

Bot, C. T., Juhasz, K., Haeussermann, F., Polonchuk, L., Traebert, M., and StoezlFeix, S. (2018). Cross - Site Comparison of Excitation-Contraction Coupling Using Impedance and Field Potential Recordings in iPSC Cardiomyocytes. *J. Pharmacol. Toxicol. Methods* 93, 46–58. doi:10.1016/j.vascn.2018.06.006

Colatsky, T., Fermini, B., Gintant, G., Pierson, J. B., Sager, P., Sekino, Y., et al. (2016). The Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative - Update on Progress. *J. Pharmacol. Toxicol. Methods* 81, 15–20. doi:10.1016/j.vascn.2016.06.002

Dempsey, G. T., Chaudhary, K. W., Atwater, N., Nguyen, C., Brown, B. S., McNelis, J. D., et al. (2016). Cardiotoxicity Screening with Simultaneous Optogenetic Pacing, Voltage Imaging and Calcium Imaging. *J. Pharmacol. Toxicol. Methods* 81, 240–250. doi:10.1016/j.vascn.2016.05.003

Eckardt, L., Breithardt, G., and Haverkamp, W. (2002). Electrophysiologic characterization of the antipsychotic drug serindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. *J. Pharmacol. Exp. Ther.* 300 (1), 64–71. doi:10.1124/pej1501.64

Food and Drug Administration, HHS (2005). International Conference on Harmonisation; Guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs; Availability. Notice. *Fed. Regist.* 70 (202), 61134–61135.

Gintant, G., Sager, P. T., and Stockbridge, N. (2016). Evolution of Strategies to Design, data analysis, and wrote manuscript), MK and VK were responsible for data analysis, FT was responsible for TI and statistical modeling, DG performed experiments, AT and DG provided scientific supports. All authors agreed to be accountable for the content of the manuscript.

**ACKNOWLEDGMENTS**

The authors wish to thank Bruce Damiano and Rajamani Sridharan for the scientific insight and review.
Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites. *Toxicol. Sci.* 170 (2), 345–356. doi:10.1093/toxsci/kfa102

Mathur, A., Loskill, P., Shao, K., Huelsch, N., Hong, S., Marcus, S. G., et al. (2015). Human iPSC-Based Cardiomyocytes for Disease Modeling and Drug Toxicity Screening. *Int. J. Mol. Sci.* 21 (19). doi:10.3390/ijms21197320

Pacher, P., Magyar, J., Szigligeti, P., Bányász, T., Pankucsi, C., Korom, Z., et al. (2020). Ovics, P., Regev, D., Baskin, P., Davidor, M., Shemer, Y., Neeman, S., et al. (2015). Testai, L., Calderone, V., Salvadori, A., Breschi, M. C., Nieri, P., and Martinotti, E. (2014). Calcium Transients Closely Refl ect Prolonged Action Potentials in iPSC-Derived Cardiomyocytes. *J. Pharmacol. Toxicol. Methods* 75, 91–100. doi:10.1016/j.vascn.2015.04.005

Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. *Cardiovasc. Res.* 58 (1), 32–45. doi:10.1016/s0008-6363(02)00846-5

Spencer, C. I., Baba, S., Nakamura, K., Hua, E. A., Sears, M. A. F., Fu, C.-c., et al. (2014). Calcium Transients Closely Refl ect Prolonged Action Potentials in iPSC Models of Inherited Cardiac Arrhythmia. *Stem Cell Rep.* 3 (2), 269–281. doi:10.1016/j.stemcr.2014.06.003

Takasuna, K., Asakura, K., Araki, S., Ando, H., Kazusa, K., Kitaguchi, T., et al. (2017). Comprehensive In Vitro Cardiac Safety Assessment Using Human Stem Cell Technology: Overview of CSAHI HEART Initiative. *J. Pharmacol. Toxicol. Methods* 83, 42–54. doi:10.1016/j.vascn.2016.09.004

Testai, L., Calderone, V., Salvadori, A., Breschi, M. C., Nieri, P., and Martinotti, E. (2004). QT Prolongation in Anaesthetized guinea-pigs: an Experimental Approach for Preliminary Screening of Torsadogenicity of Drugs and Drug Candidates. *J. Appl. Toxicol.* 24 (3), 217–222. doi:10.1002/jat.975

Tither, K., Girodet, P.-O., Verdoux, H. I. n., Molimard, M., B?quad, B., Havenkamp, W., et al. (2005). Atypical Antipsychotics. *Drug Saf.* 28 (1), 35–51. doi:10.2165/00002018-200528010-00003

Watanabe, H., Honda, Y., Deguchi, J., Yamada, T., and Bando, K. (2017). Usefulness of Cardiototoxicity Assessment Using Calcium Transient in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *J. Toxicol. Sci.* 42 (4), 519–527. doi:10.2131/jts.42.519

Woosley, R. L., Black, K., Heise, C. W., and Romero, K. (2018). CredibleMeds.org: What Does it Offer? *Trends Cardiovasc. Med.* 28 (2), 94–99. doi:10.1016/j.tcm.2017.07.010

Zeng, H., Roman, M. I., Lis, E., Lagrutta, A., and Sannahust, F. (2016). Use of FDSS/μCell Imaging Platform for Preclinical Cardiac Electrophysiology Safety Screening of Compounds in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *J. Pharmacol. Toxicol. Methods* 81, 217–222. doi:10.1016/j.vascn.2016.05.009

Zhang, X., Guo, L., Zeng, H., White, S. L., Furniss, M., Balasubramanian, B., et al. (2016). Multi-parametric Assessment of Cardiomyocyte Excitation-Contraction Coupling Using Impedance and Field Potential Recording: A Tool for Cardiac Safety Assessment. *J. Pharmacol. Toxicol. Methods* 81, 201–216. doi:10.1016/j.vascn.2016.06.004

**Conflict of Interest:** Authors HL, MK, VK, FT, DG, AT and DG are employed by Janssen Pharmaceutica NV.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Lu et al.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.